| Full Name | Kana |
|---|---|
| Speciality | Clinic/Center |
| Location | 3449 E Rezanof Dr, Kodiak, Alaska |
| Authorized Official Name and Position | Mike Pfeffer (CEO) |
| Authorized Official Contact | 9074869800 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Kana 3449 E Rezanof Dr Kodiak AK 99615-6952 Ph: (907) 486-9800 | Kana 3449 E Rezanof Dr Kodiak AK 99615-6952 Ph: (907) 486-9800 |
| NPI Number | 1679514236 |
|---|---|
| Provider Enumeration Date | 06/08/2006 |
| Last Update Date | 02/28/2024 |
| Medicare PECOS PAC ID | 8426959297 |
|---|---|
| Medicare Enrollment ID | O20041004000838 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679514236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QC1500X | Clinic/center - Community Health | (* (Not Available)) | Primary |
| Provider Name | Elizabeth D. Ferucci |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1598705121 PECOS PAC ID: 2163418567 Enrollment ID: I20040421001677 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Charles C Edwards |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1447291067 PECOS PAC ID: 3476448796 Enrollment ID: I20050302000119 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Youssef K Barbour |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1588846042 PECOS PAC ID: 5991888067 Enrollment ID: I20080212000715 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Matthew J Schnellbaecher |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1942233481 PECOS PAC ID: 1557440211 Enrollment ID: I20080506000563 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | David G Chamberlain |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1407895949 PECOS PAC ID: 2062562929 Enrollment ID: I20090615000605 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Sam J Chelmo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275794778 PECOS PAC ID: 4385819242 Enrollment ID: I20111205000938 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Robert W Davis |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1932172178 PECOS PAC ID: 7911050810 Enrollment ID: I20131028001588 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Laura L Shively |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1174797088 PECOS PAC ID: 1254568231 Enrollment ID: I20131219000400 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Elise M Pletnikoff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598056590 PECOS PAC ID: 4789813387 Enrollment ID: I20140130001541 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Christy S Pierce |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639349798 PECOS PAC ID: 6507923919 Enrollment ID: I20140614000013 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Evan Jones |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275829517 PECOS PAC ID: 8022239524 Enrollment ID: I20141027001765 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Matthew S Ubedei |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1962681171 PECOS PAC ID: 3971720954 Enrollment ID: I20150710001908 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Derek Jay Bowers |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871933465 PECOS PAC ID: 9931338894 Enrollment ID: I20160401001563 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Sarah M Doaty |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1215254818 PECOS PAC ID: 2668767211 Enrollment ID: I20160823000164 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Lilian K Ho |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1659798114 PECOS PAC ID: 4981925476 Enrollment ID: I20171020000831 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Tirza A Cannon |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1275842510 PECOS PAC ID: 1759607013 Enrollment ID: I20171107001045 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Mark Burkart |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1467829721 PECOS PAC ID: 2163771486 Enrollment ID: I20180821000256 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Jacob Miller |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912522012 PECOS PAC ID: 0446672281 Enrollment ID: I20200623003473 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Linda G Berry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356645097 PECOS PAC ID: 3678744398 Enrollment ID: I20200928002463 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Katie Jane Gray |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174055644 PECOS PAC ID: 0345518148 Enrollment ID: I20201228001691 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Elizabeth Litoff |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1437641545 PECOS PAC ID: 7517361751 Enrollment ID: I20210810001237 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Jordan S Gardner |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1467728261 PECOS PAC ID: 5799083168 Enrollment ID: I20211203002255 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Rachel C Jermann |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699204529 PECOS PAC ID: 3274899687 Enrollment ID: I20220302002442 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Alison E Horn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942962170 PECOS PAC ID: 9133514854 Enrollment ID: I20220316001215 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Kaytlin Erin Rupert |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215356928 PECOS PAC ID: 9335522895 Enrollment ID: I20220816001144 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Matthew Markey-crimp |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366903171 PECOS PAC ID: 3072842764 Enrollment ID: I20220909001436 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Myles Sorokovsky |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700432762 PECOS PAC ID: 5799112041 Enrollment ID: I20230329000050 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Raul Mendez Guevara |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235860925 PECOS PAC ID: 7618332123 Enrollment ID: I20230504001831 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Adriana Rosas Masi |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1922494517 PECOS PAC ID: 6507172897 Enrollment ID: I20231129001838 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Shantai Mcdermott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093112898 PECOS PAC ID: 6507169984 Enrollment ID: I20231218000704 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
| Provider Name | Colby Ray Perez |
|---|---|
| Provider Type | Practitioner - Marriage And Family Therapist |
| Provider Identifiers | NPI Number: 1568970549 PECOS PAC ID: 1254774805 Enrollment ID: I20240209003876 |
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
News Archive
In today's headlines, details and analysis of President Barack Obama's debt-reduction plan, which would trim health programs by $320 billion and links such entitlement trims to new taxes.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
The age-old adage "I'll sleep on it" has proven to be scientifically sound advice, according to a new study which measured changes in people's brain activity and responses before and after a nap.
A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.
› Verified 9 days ago
Kodiak Area Native Association Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3449 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-9800 Fax: 907-486-9897 | |
North Pacific Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 104 Center Ave, Ste 100, Kodiak, AK 99615 Phone: 907-486-4183 Fax: 907-486-4233 | |
Kodiak Area Native Association Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3449 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-9868 Fax: 907-486-9884 | |
Arctic Chiropractic & Massage Kodiak Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2975 Mill Bay Rd Ste A, Kodiak, AK 99615 Phone: 907-512-0809 Fax: 907-512-0828 | |
Kodiak Island Medical Associates Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1818 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-6065 Fax: 907-486-2248 | |
Rockmore-king Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Building N46 Cape Sarichef, Kodiak, AK 99619 Phone: 907-487-5757 Fax: 907-487-5360 |